Derm Fall Clinical

In this interview on the conference floor at Fall Clinical Dermatology, Dr. Lio discussed the important topic of treating patients with eczema that have skin of color.

Results of several clinical trials demonstrated the superior efficacy of risankizumab compared with apremilast or placebo.

This presentation at the Fall Clinical Dermatology conference in Las Vegas explored the topic of advancements in HS treatment.

Benjamin Lockshin, MD, explains the current landscape of oral medications for plaque psoriasis, emerging developments in treatment, and the importance of shared decision-making.

An investigator argues for greater prescriber understanding and communication of real-world efficacy and safety outcomes for the latest oral JAK inhibitor approved for atopic dermatitis.

In this Q&A interview, Dr. Glick delved into the topics covered in his conference presentation on treating adults with plaque psoriasis and psoriatic arthritis.

Oral JAK-1 inhibitors upadacitinib and povorcitinib are showing significant benefit for patients with HS, and may soon be up for FDA decision.

In this Q&A interview, Del Rosso discussed his presentation on eczema therapies, the updates he made to his conference presentations this year, as well as his outlook on future research.

This interview with Dr. Bhatia featured a discussion about his views on newer therapies for dermatologic conditions as well as his outlook on the current research landscape.

In this segment of her interview, Hebert went further in depth about the main points covered in her conference talk regarding new developments in pediatric dermatology.

This interview featured a discussion with Dr. Hebert in which she addressed the biggest takeaways of her conference presentation titled ‘What’s New in Pediatric Dermatology.’

This interview segment featured Dr. Alexis describing his views on the ways in which the dermatology field may be able to better address disparities in care for those with skin of color.

Cases have increased annually; a clinician shares his strategy for remaining aggressive and diligent in prevention and management.

In this interview, Dr. Alexis spoke about the ways in which the dermatology field should address the needs of patients with skin of color.

In this segment, Dr. Del Rosso discussed a conference presentation he gave titled ‘What You Really Need to Know About Rosacea.’

Secukinumab and bimekizumab may reach the market soon for the treatment of HS. What will it provide patients?

In this interview, Dr. Bhatia described the main takeaways from his conference presentation titled ‘JAKs and TYKs - What you Need to Know.’

The cross-specialty collaboration between dermatologists and these fields has been a daily occurrence, as inflammation-targeting drugs and comorbid patients have brought team closer together.

During the next part of his Q&A interview, Dr. Lebwohl further described new and future research into treating psoriasis.

Since roflumilast cream was approved by the FDA last July, one dermatology physician assistant advocates for its use as a primary medication.

This Q&A interview with Dr. Lebwohl featured a discussion about which therapies may be the best for patients who have psoriasis.

The introduction of the TYK2 inhibitor is the latest advancement toward cross-specialty care with systemic agents.

Ahead of Fall Clinical Dermatology 2023 Conference for PAs & NPs, Glick discusses how the COVID-19 reshaped dermatology roles, and the value of physician assistants and nurse practitioners in the current care team.

Dr. Del Rosso spoke regarding his conference presentation, titled ‘What’s New in the Medicine Chest,’ in which he describes newer therapies in the dermatology field.

New phase 3 data shared at Fall Clinical Dermatology show the IL-13 inhibitor maintained skin clearance observed at 16 weeks.

After the announced recall of dry shampoo products by Unilever this month, dermatologists anticipate an uptick in patient concerns.

Lawrence Eichenfield, MD, discusses recent achievements in identifying and possibly preventing atopic dermatitis development in infants.

With dupilumab already available and JAK inhibitors on the way, clinicians have a bevy of treatments designated for pediatric patients.

Brett King, MD, PhD, explains the altered screening and care strategies for patients following baricitinib's approval.

Real-world analysis comparing systemic therapies show dupilumab better improves EASI and quality of life among affected children.